![Mahmoud Mahmoudian](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mahmoud Mahmoudian
Directeur/Membre du Conseil chez BioEclipse Therapeutics, Inc.
Postes actifs de Mahmoud Mahmoudian
Sociétés | Poste | Début | Fin |
---|---|---|---|
BioEclipse Therapeutics, Inc.
![]() BioEclipse Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioEclipse Therapeutics, Inc. engages in the development of curative immune-oncology therapeutics for patient with cancer. Its patented immunotherapy is the CRX-100, which delivers potentially curative treatments to patients over a broad range of tumor type. The company was founded by Pamela R. Contag, Christopher Contag, and Robert Negrin and is headquartered in San Francisco, CA. | Directeur/Membre du Conseil | 28/01/2022 | - |
Historique de carrière de Mahmoud Mahmoudian
Statistiques
Internationale
Etats-Unis | 2 |
Opérationnelle
Director/Board Member | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
BioEclipse Therapeutics, Inc.
![]() BioEclipse Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioEclipse Therapeutics, Inc. engages in the development of curative immune-oncology therapeutics for patient with cancer. Its patented immunotherapy is the CRX-100, which delivers potentially curative treatments to patients over a broad range of tumor type. The company was founded by Pamela R. Contag, Christopher Contag, and Robert Negrin and is headquartered in San Francisco, CA. | Health Technology |
- Bourse
- Insiders
- Mahmoud Mahmoudian
- Expérience